North America Monoclonal Antibodies Market by Source (Murine, Chimeric, Humanized, Human) by Indication (Cancer, Autoimmune diseases, infectious diseases, Cardiovascular diseases, CNS disorders, others) by End-User (Hospitals/Clinics, Research Institute, Diagnostic Laboratories) by Application (Medical, Experimental) and by Region - Industry Analysis, Size, Share, Growth, Trends, and Forecasts (2016–2021)

North America Monoclonal Antibodies Market by Source (Murine, Chimeric, Humanized, Human) by Indication (Cancer, Autoimmune diseases, infectious diseases, Cardiovascular diseases, CNS disorders, others) by End-User (Hospitals/Clinics, Research Institute, Diagnostic Laboratories) by Application (Medical, Experimental) and by Region - Industry Analysis, Size, Share, Growth, Trends, and Forecasts (2016–2021)

ID: 1185 | Pages: 179 | November 2016 | Region: North America


North America Monoclonal Antibodies Market was worth $36391.9756 million in 2016 and is estimated to grow at a CAGR of 6.24%, to reach $49254.5 million by 2021. The market is showcasing evident potential in the mentioned forecasting period. mAb`s are antibodies produced by a single clone of cells consisting of identical antibody molecules. North America market for monoclonal antibodies continues to grow tremendously with fast adoption for various indications.

Monoclonal Antibodies have wide range of applications in different diseases such as cancer, autoimmune diseases, infectious diseases etc. Currently there around forty-seven monoclonal antibody products that have been approved for the treatment of a wide range of diseases. In the past five years 3-6 new products were approved every year supporting the growth of North America monoclonal antibodies market.

North America Monoclonal Antibodies market is driven by high rate of product approvals, along with rising adaptation of both diagnostic and therapeutic antibodies. Increasing R & D activities is also a major factor fuelling the growth of the market. Rising awareness levels among patients and physicians regarding various applications of mAb is also a key factor adding upto the market growth. However huge cost involved in their development the major factor restraining the growth of the market. Lengthy product approval pathway is also noteworthy factor hindering the market.

North America Monoclonal Antibodies is broadly segmented into Source, Indication, End User and Application. On the basis of source, the market is categorized into Murine, Chimeric, Humanized and Human. Human mAb`s is the largest segment by source accounting for a share of around XX%. By indication the market is segmented into cancer, Auto immune diseases, Infectious diseases, Cardiovascular diseases, CNS disorders and others. Cancer Vaccines are further sub segmented into Blood Cancer, Breast Cancer, Colorectal Cancer, Lung Cancer, Pancreatic Cancer and Others. Based on end user, the market is segmented into Hospitals/Clinics, Research Institute and Diagnostic Laboratories. Hospitals is the largest end user segment accounting for a share of approximately XX%. By application North America monoclonal antibodies market is segmented into medical and experimental. Based on experimental the market is further sub segmented into Western Blot, ELISA, Radioimmune Assays, Immunofluorescence and others.

Geographically, North America monoclonal antibodies market is segmented into United States and Canada. United States is the largest market for mAb`s while Canada is estimated to be the fastest growing due to growing awareness about the antibody products.

Some of the major companies dominating the market, by their products include GlaxoSmithKline plc (U.K.), Novartis AG (Switzerland), Pfizer Inc. (U.S.), Thermo Fisher Scientific Inc. (U.S.), Eli Lilly and Company (U.S.), Seattle Genetics (U.S.), Bristol-Myers Squibb (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland) and Biogen Inc.(U.S.).

 

1.Introduction                                  

                1.1 Market Definition                    

                1.2 Study Deliverables                  

                1.3 Base Currency, Base Year and Forecast Periods                           

                1.4 General Study Assumptions                

2. Research Methodology                                           

                2.1 Introduction                              

                2.2 Research Phases                      

                                2.2.1 Secondary Research            

                                2.2.2 Primary Research 

                                2.2.3 Econometric Modelling     

                                2.2.4 Expert Validation  

                2.3 Analysis Design                         

                2.4 Study Timeline                          

3. Overview                                      

                3.1 Executive Summary                

                3.2 Key Inferences                         

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)                                      

                4.1 Market Drivers                          

                4.2 Market Restraints                    

                4.3 Key Challenges                         

                4.4 Current Opportunities in the Market               

5. Market Segmentation                                              

                5.1 By Source                    

                                5.1.1 Murine     

                                5.1.2 Chimeric  

                                5.1.3 Humanized             

                                5.1.4 Human     

                5.2 By Indication                              

                                5.2.1 Cancer      

                                                5.2.1.1 Blood Cancer

                                                5.2.1.2 Breast Cancer

                                                5.2.1.3 Colorectal Cancer

                                                5.2.1.4 Lung Cancer

                                                5.2.1.5 Pancreatic Cancer

                                                5.2.1.6 Others

                                5.2.2 Autoimmune Diseases       

                                5.2.3 Infectious Diseases             

                                5.2.4 Cardiovascular Diseases    

                                5.2.5 CNS Disorders       

                                5.2.6 Others (Inflammatory, Microbial Diseases, & Other)             

                5.3 End User                     

                                5.3.1 Hospitals/Clinics   

                                5.3.2 Research Institute

                                5.3.3 Diagnostic Laboratories     

                5.4 Application                 

                                5.4.1 Medical    

                                5.4.2 Experimental         

                                                5.4.2.1 Western Blot

                                                5.4.2.2 ELISA

                                                5.4.2.3 Radioimmune Assays 

                                                5.4.2.4 Immunofluorescence 

                                                5.4.2.5 Other (Immunohistochemistry, Immunoprecipitation, & Immunocytochemistry)

6. Geographical Analysis                                              

                6.1 North America                          

                                6.1.1 Introduction           

                                6.1.2 United States         

                                6.1.3 Canada     

7. Pipeline Product Analysis                                        

                7.1 Overview                    

                7.2 Pipeline Development Landscape                     

                7.3 Molecular Targets in the Pipeline                      

                7.4 Clinical Trials                              

                                7.4.1 Failure Rate by Stage of Development, Indication, Molecule Type and Molecular Target       

                                7.4.2 Clinical Trial Duration by Stage of Development, Indication, Molecule Type and Molecular Target                

                                7.4.3 Clinical Trial Size by Stage of Development, Indication, Molecule Type and Molecular Target               

                7.5 Key Trends in Monoclonal Antibodies Development                 

                                7.5.1 Targeted Therapies             

                7.6 Promising Monoclonal Antibodies in Pipeline                              

                7.7 Heat Map of Safety and Efficacy for Pipeline and Marketed Monoclonal Antibodies                   

8.Strategic Analysis                                        

                8.1 PESTLE analysis                         

                                8.1.1 Political     

                                8.1.2 Economic 

                                8.1.3 Social         

                                8.1.4 Technological         

                                8.1.5 Legal          

                                8.1.6 Environmental      

                8.2 Porter’s Five analysis                              

                                8.2.1 Bargaining Power of Suppliers        

                                8.2.2 Bargaining Power of Consumers    

                                8.2.3 Threat of New Entrants     

                                8.2.4 Threat of Substitute Products and Services

                                8.2.5 Competitive Rivalry within the Industry      

9.Market Leaders' Analysis                                          

                9.1 GlaxoSmithKline plc (U.K.)                   

                                9.1.1 Overview

                                9.1.2 Product Analysis   

                                9.1.3 Financial analysis  

                                9.1.4 Recent Developments       

                                9.1.5 SWOT analysis       

                                9.1.6 Analyst View          

                9.2 Novartis AG (Switzerland)                    

                9.3 Pfizer Inc. (U.S.)                       

                9.4 Thermo Fisher Scientific Inc. (U.S.)                   

                9.5 Eli Lilly and Company (U.S.)                 

                9.6 Seattle Genetics (U.S.)                          

                9.7 Bristol-Myers Squibb (U.S.)                 

                9.8 F. Hoffmann-La Roche Ltd. (Switzerland)                       

                9.9 Biogen Inc.(U.S.)                      

10.Competitive Landscape                                          

                10.1 Market share analysis                          

                10.2 Merger and Acquisition Analysis                     

                10.3 Agreements, collaborations and Joint Ventures                       

                10.4 New Product Launches                       

11.Market Outlook & Investment Opportunities                               

Appendix                                           

                a) List of Tables                

                b) List of Figures                              

  • Regional and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
  • Segment-level analysis in terms of technology, component, and type along with market size forecasts and estimations to detect key areas of industry growth in detail
  • Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analysing the level of competition and business strategy development
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market

TitlePriceAdd To Cart
  1. North America Monoclonal Antibodies Market By Murine, From 2016-2021 ( USD Million )
  2. North America Chimeric Market By Region, From 2016-2021 ( USD Million )
  3. North America Humanized Market By Region, From 2016-2021 ( USD Million )
  4. North America Human Market By Region, From 2016-2021 ( USD Million )
  5. North America Monoclonal Antibodies Market By Cancer, From 2016-2021 ( USD Million )
  6. North America Autoimmune Diseases Market By Region, From 2016-2021 ( USD Million )
  7. North America Infectious Diseases Market By Region, From 2016-2021 ( USD Million )
  8. North America Cardiovascular Diseases Market By Region, From 2016-2021 ( USD Million )
  9. North America CNS Disorders Market By Region, From 2016-2021 ( USD Million )
  10. North America Others (Inflammatory, Microbial Diseases, & Other) Market By Region, From 2016-2021 ( USD Million )
  11. North America Monoclonal Antibodies Market By Hospitals/Clinics, From 2016-2021 ( USD Million )
  12. North America Research Institute Market By Region, From 2016-2021 ( USD Million )
  13. North America Diagnostic Laboratories Market By Region, From 2016-2021 ( USD Million )
  14. North America Monoclonal Antibodies Market By Medical, From 2016-2021 ( USD Million )
  15. North America Experimental Market By Region, From 2016-2021 ( USD Million )
  16. United States Monoclonal Antibodies Market By Murine, From 2016-2021 ( USD Million )
  17. United States Monoclonal Antibodies Market By Cancer, From 2016-2021 ( USD Million )
  18. United States Monoclonal Antibodies Market By Hospitals/Clinics, From 2016-2021 ( USD Million )
  19. United States Monoclonal Antibodies Market By Medical, From 2016-2021 ( USD Million )
  20. Canada Monoclonal Antibodies Market By Murine, From 2016-2021 ( USD Million )
  21. Canada Monoclonal Antibodies Market By Cancer, From 2016-2021 ( USD Million )
  22. Canada Monoclonal Antibodies Market By Hospitals/Clinics, From 2016-2021 ( USD Million )
  23. Canada Monoclonal Antibodies Market By Medical, From 2016-2021 ( USD Million )
  24. North America Monoclonal Antibodies Market By Blood Cancer, From 2016-2021 ( USD Million )
  25. North America Breast Cancer Market By Region, From 2016-2021 ( USD Million )
  26. North America Colorectal Cancer Market By Region, From 2016-2021 ( USD Million )
  27. North America Lung Cancer Market By Region, From 2016-2021 ( USD Million )
  28. North America Pancreatic Cancer Market By Region, From 2016-2021 ( USD Million )
  29. North America Others Market By Region, From 2016-2021 ( USD Million )
  30. United States Monoclonal Antibodies Market By Blood Cancer, From 2016-2021 ( USD Million )
  31. Canada Monoclonal Antibodies Market By Blood Cancer, From 2016-2021 ( USD Million )
  32. North America Monoclonal Antibodies Market By Western Blot, From 2016-2021 ( USD Million )
  33. North America ELISA Market By Region, From 2016-2021 ( USD Million )
  34. North America Radioimmune Assays Market By Region, From 2016-2021 ( USD Million )
  35. North America Immunofluorescence Market By Region, From 2016-2021 ( USD Million )
  36. North America Others Market By Region, From 2016-2021 ( USD Million )
  37. United States Monoclonal Antibodies Market By Western Blot, From 2016-2021 ( USD Million )
  38. Canada Monoclonal Antibodies Market By Western Blot, From 2016-2021 ( USD Million )

"We Think Through Different Layers, We Work Across Different Verticals."

Market Data Forecast, Inc.
502, kakatiya's empire,
Jubilee Gardens,
Hyderabad, India.
+1-888-702-9626 (U.S. TOLL FREE)
contact@marketdataforecast.com


Subscribe To Our News Letter

Or follow us on social platform

© 2017 Market Data Forecast
All Rights Reserved.